To include your compound in the COVID-19 Resource Center, submit it here.

Tysabri natalizumab regulatory update

Biogen Idec updated the U.S. label for autoimmune drug Tysabri natalizumab to warn

Read the full 139 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE